On November 4, 2022 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, reported that it will present a poster on the combination module of the Phase 1 clinical study (clinicaltrials.gov NCT03447470) of RXC004 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Conference (8-12 November 2022, Boston, MA) (Press release, Redx Pharma, NOV 4, 2022, View Source [SID1234623109]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster will present results from the combination module of the Phase 1 clinical study in which RXC004 was combined with nivolumab, an anti-PD-1 antibody, in patients with advanced solid tumours. RXC004 is a clinical stage, highly potent and selective, orally active Porcupine inhibitor being developed as a targeted therapy for Wntligand dependent cancer.

RXC004 is currently being evaluated in two Phase 2 proof-of-concept clinical studies in genetically selected metastatic colorectal cancer (mCRC) (clinicaltrials.gov NCT04907539), and in biliary tract cancers and genetically selected pancreatic cancer (clinicaltrials.gov NCT04907851). Following the completion of this Phase 1 combination study, the Company will now initiate enrolment into combination cohorts of RXC004 with anti-PD-1 antibodies in mCRC and biliary tract cancers, within these Phase 2 studies.